Table 1
Clinic-pathological characteristics of patients
Nivolumab or pembrolizumab
N (%)
Total
41 (100)
Median age
Range (23–85)
64
Gender
Male
26 (63.4)
Female
15 (36.6)
Disease stage
III
6 (14.6)
IV
35 (85.4)
Line of treatment
I
17 (41.5)
II
17 (41.5)
>III
7 (17)